tbuckley/cabot-search huggingface dataset:
CD40 Ligand Determines Whether Interleukin 21 Induces Differentiation of Human B Cells Into Plasma Cells or Into Granzyme B-Secreting Cytotoxic Cells.
Authors: Bernd Jahrsdoerfer, Magdalena Hagn, Kai Sontheimer, Elisabeth Schwesinger, Verena Ebel, Julia Maier, Thamara Beyer, Dorit Fabricius, Oleg Lunov, Kyrylo Tron, Tatjana Syrovets, Thomas FE Barth, G. Ulrich Nienhaus, Thomas Simmet
Journal: Blood (2009)
What is a Lung Nodule?
Authors: Christopher G Slatore, Renda Soylemez Wiener, Amber D Laing
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Why have I been given this handout?One or more lung nodules were seen on your recent chest x-ray or CT ("CAT") scan. How common are lung nodules?Nodules are found in up to half of adults who get a chest x-ray or CT scan. Do nodules cause any symptoms?In general, small nodules don't cause any noticeable problems.They're too small to cause pain or breathing problems. How big is the nodule?Your healthcare team can tell you the exact size of your nodule.Most nodules are less than 10 millimeters (about a ½ inch) Here are the sizes of some common fruits & vegetables for comparison. Should I worry that I have a nodule?Most nodules are not cancer, but for a small number of people the nodule may turn out to be an early cancer.The best ways to tell if a nodule is cancer are by: 1. Seeing how it looks on the CT scan.2. Seeing whether it grows over time.A nodule that grows larger over time is a sign that it could be a cancer.3. Taking a sample of the nodule with a needle or surgery.Most people with a nodule will NOT need to have this test.
Prophylaxis and Treatment of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation: A Survey on Center Strategies by the European Group for Blood and Marrow Transplantation (EBMT)
Authors: Tapani Ruutu, Anja van Biezen, Bernd Hertenstein, Anja Henseler, Laurent Garderet, Jakob Passweg, Vanderson Rocha, Riccardo Saccardi, Anna Sureda, Alois Gratwohl, Dietger Niederwieser, Theo de Witte
Journal: Blood (2010)
Cross-cultural adaptation, evaluation and validation of the Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE): a study protocol
Authors: C. Caminiti, M. Bagnalasta, F. Arpinelli, M. Bassi, P. Betteto, J. Bryce, L. Del Mastro, D. De Persis, F. Diodati, E. Iannelli, A.L. Nicelli, R. Passalacqua, C. Piparo, C. Porta, F. Perrone
Journal: Annals of Oncology (2015)
A phase III study of receptor-targeted <sub>99m</sub>Tc-tilmanocept versus blue dye in the evaluation of SLNs in breast cancer and melanoma.
Authors: F. O. Cope, V. K. Sondak, A. M. Wallace
Journal: Journal of Clinical Oncology (2011)

LBA8526^ The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed onsite at the Meeting on June 4, 2011, and as a supplement to the June 20, 2011, issue of Journal of Clinical Oncology.
Unique Gain-of-Function of Mutated c-CBL Tumor Suppresor in Myeloid Neoplasms.
Authors: Masashi Sanada, Takahiro Suzuki, Lee-Yung Shih, Makoto Otsu, Motohiro Kato, Satoshi Yamazaki, Hiroaki Honda, Mamiko Yanagimoto Sakata, Keiki Kumano, Hideaki Oda, Junko Takita, Norihiko Kawamata, Masafumi Onodera, Yasuhide Hayashi, Mineo Kurokawa, Shigeru Chiba, Hiraku Mori, Keiya Ozawa, Mitsuhiro Omine, Hiromitsu Nakauchi, Phillip H Koeffler, Seishi Ogawa
Journal: Blood (2009)
Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL).
Authors: Dieter Hoelzer, Nicola Goekbuget, Joachim Beck, Thomas Burmeister, Aristoteles Giagounidis, Axel Glasmacher, Heike Pfeifer, Harald Rieder, Mathias Schmid, Eckhard Thiel, Barbara Wassmann, Oliver Ottmann
Journal: Blood (2004)
Analysis of the risk of fracture in an unselected cohort of patients undergoing androgen deprivation.
Authors: R. D. Ennis, K. J. Clerkin, S. M. Cohen
Journal: Journal of Clinical Oncology (2011)

193 Background: Androgen deprivation therapy (ADT) is a therapeutic approach for men with various prostate cancer disease states. Treatment related side effects of ADT include rapid bone loss. A large 2005 NEJM study found that the bone loss related to ADT leads to the development of fractures. Methods: This is a retrospective cohort study of patients treated with ADT in a radiation oncology (RDE) and medical oncology (SC) practice at an urban academic medical center from 1998-2010. Patients with evidence of bone metastases responsive to ADT were included. Those with androgen independent prostate cancer were excluded. Results: 130 patients met the criteria for inclusion and had the characteristics listed in the table. Among the 130 only 3 fractures occurred during 373 patient years of follow up, all within 5 months of ADT initiation. The fracture free survival (FFS) rate at 3 years for all was 97.7%. Excluding fractures occurring within 6 months of ADT initiation the FFS rate was 100% at 3 years. No significant difference was demonstrated in those screened with a pretreatment DEXA scan; there was no relationship between the number of AD cycles, recovery of testosterone to normal or total time on AD. Those with any baseline risk factor of osteoporosis had a trend to an increased risk of fractures (p=0.065); older patients, surprisingly, had a lower risk (p=0.054). Patients with normal BMD had a FFS of 93.8% at 3 yrs, osteopenic patients had 94.7%, and patients with osteoporosis and hormone responsive metastases had 100%. Conclusions: The prevalence of fracture among this group is significantly less than what has previously been reported for men receiving ADT, potentially suggesting an overstatement of risk. Further prospective study with a larger sample size is needed. [Table: see text] No significant financial relationships to disclose.
Splice Variant JAK2 Transcript Deleting Exon 14 in Patients with Chronic Myeloproliferative Neoplasms.
Authors: Wanlong Ma, Hagop Kantarjian, XI Zhang, Xiuqiang Wang, Zhong Zhang, Chen-Hsiung Yeh, Anthony Sferruzza, Susan O'Brien, Maher Albitar
Journal: Blood (2009)
Chromosomes 2q, 4q and 13q21 Are Preferential Targets of Epstein-Barr Virus (EBV) Integration In Burkitt's Lymphoma Cell Lines
Authors: Eva Maria Murga Penas, Juliane Hinke, Petra Behrmann, Snjezana Janjetovic, Georgia Schilling, Carsten Bokemeyer, Judith Dierlamm
Journal: Blood (2010)
High Dose and Conventional Anthracycline Regimen for Adult Non-Hodgkin’s Primary Bone Lymphoma (PBL). A GOELAMS’s Trial.
Authors: Aline Schmidt-Tanguy, Bernard Desablens, Thierry Lamy, Marc Bernard, Delphine Senecal, Jean-Francois Abgrall, Philippe Casassus, Jacqueline Dugay, Philippe Rodon, Mathilde Hunault-Berger, Norbert Ifrah, Philippe Colombat
Journal: Blood (2004)
Autologous (auto) Versus Allogeneic (allo) Hematopoietic Cell Transplantation (HCT) for T-NHL: A CIBMTR Analysis
Authors: Sonali Smith, Linda J Burns, Koen van Besien, Jennifer LeRademacher, Wensheng He, Ginna G. Laport, Silvia Montoto, David G Maloney, Parameswaran Hari
Journal: Blood (2010)
FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: A randomized phase II study.
Authors: Nils Glenjen, Katrin Hammerling, Ingunn Hatlevoll, Rune Småland, Petra Weber Hauge, Geir Egil Eide, Halfdan Sorbye, Olav Dahl, Gunilla Frykholm
Journal: Journal of Clinical Oncology (2012)

71 Background: The Norwegian Gastrointestinal Cancer Group (NGICG) conducted a phase II randomized study comparing the efficacy and safety of FLOX and FLIRI as first line treatment in metastatic or locally advanced gastric cancer. At progression or unacceptable drug related toxicity, a crossover to the other treatment arm should be done, if second line chemotherapy was indicated. Methods: 66 patients from 6 treatment centers in Norway were randomized to FLOX (oxaliplatin 85 mg/m 2 on day 1, bolus 5-FU 500 mg/m 2 and FA 60 mg/m 2 on day 1 and 2, or FLIRI (irinotecan 180 mg/m 2 on day 1, bolus 5-FU 500 mg/m 2 and FA 60 mg/m 2 on day 1 and 2). Both treatments were repeated every second week. The primary endpoint was response rate (RR) and time to progression (TTP). Secondary endpoints were overall survival (OS) and safety data. Results: At the present time data from 63 patients are available for analysis. First-line treatment: FLOX (n = 32) versus (v.) FLIRI (n = 31): Complete response (CR) n = 0 in both arms, partial response (PR) n = 16 v. 9, stable disease (SD) n = 12 v. 13, progressive disease (PD) n = 3 v. 6, not assessable for evaluation n = 1 v. 3 patients. RR was 50 % in the FLOX arm v. 29 % in the FLIRI arm, p = not significant (n.s), Pearson Chi-Square test. Median TTP was 5 months (95 % CI 2.2-7.8) v. 4 months (95 % CI 2.2-5.8), p = n.s, median OS was 11 months (95 % CI 9.2-12.8 ) v. 10 months (95 % CI 5.7-14.3), p = n.s, Log Rank test. Patient characteristics were well balanced. Febrile neutropenia was present among 10 % of the patients in the FLOX arm versus 7 % in the FLIRI arm. Second line treatment: 30 patients received second line treatment with FLOX or FLIRI. Data regarding RR, TTP, OS and safety will be updated in December 2011. Conclusions: The FLOX and FLIRI regimens are well tolerated among patients with locally advanced and metastatic gastric cancer. As first line treatment the FLOX regime had a higher RR of 50% v. 29% for the FLIRI regime, longer TTP; 5 v. 4 months and longer OS 11 v. 10 months, but the difference did not reach statistical significance.
Molecular evolution of two distinct <i>dmrt1</i> promoters for germ and somatic cells in vertebrate gonads
Authors: Shuuji Mawaribuchi, Masato Musashijima, Mikako Wada, Yumi Izutsu, Erina Kurakata, Min Kyun Park, Nobuhiko Takamatsu, Michihiko Ito
Journal: Molecular Biology and Evolution (2016)

The transcription factor DMRT1 has important functions in two distinct processes, somatic-cell masculinization and germ-cell development in mammals. However, it is unknown whether the functions are conserved during evolution, and what mechanism underlies its expression in the two cell lineages. Our analysis of the Xenopus laevis and Silurana tropicalis dmrt1 genes indicated the presence of two distinct promoters: one upstream of the noncoding first exon (ncEx1), and one within the first intron. In contrast, only the ncEx1-upstream promoter was detected in the dmrt1 gene of the agnathan sand lamprey, which expressed dmrt1 exclusively in the germ cells. In X. laevis, the ncEx1- and exon 2-upstream promoters were predominantly used for germ-cell and somatic-cell transcription, respectively. Importantly, knockdown of the ncEx1-containing transcript led to reduced germ-cell numbers in X. laevis gonads. Intriguingly, two genetically female individuals carrying the knockdown construct developed testicles. Analysis of the reptilian leopard gecko dmrt1 revealed the absence of ncEx1. We propose that dmrt1 regulated germ-cell development in the vertebrate ancestor, then acquired another promoter in its first intron to regulate somatic-cell masculinization during gnathostome evolution. In the common ancestor of reptiles and mammals, only one promoter got function for both the two cell lineages, accompanied with the loss of ncEx1. In addition, we found a conserved noncoding sequence (CNS) in the dmrt1 5ʹ-flanking regions only among amniote species, and two CNSs in the introns among most vertebrates except for agnathans. Finally, we discuss relationships between these CNSs and the promoters of dmrt1 during vertebrate evolution.
Targeting the Tumor Evasion Interaction of NKG2A and Its Ligand HLA-E Increases Natural-Killer Cell Activity in Chronic Lymphocytic Leukemia
Authors: Emily McWilliams, Jennifer M Mele, Faraz Fiazuddin, Carolyn Cheney, Natarajan Muthusamy, Farrukh T. Awan
Journal: Blood (2015)
Acute hemorrhagic conjunctivitis outbreaks caused by coxsackievirus A24v - Uganda and Southern Sudan, 2010.
Authors: J. Wamala, I. Makumbi, M. Mugagga, B. Bakamutumaho, S. Wasike, R. Downing, A. L. Kirbak, T. Ugiji, J. J. Hassen, A. G. Abias, J. Lagu, N. Atem, K. M. Yona, A. Abubakar, M. K. Njenga, L. Nderitu, S. L. Rogers, M. Pallansch, B. Whitaker, D. D. Erdman, E. Schneider
Journal: MMWR Morbidity and Mortality Weekly Report (2010)
Bowel morbidity after prostate brachytherapy with Cesium-131 assessed by longitudinal EPIC survey.
Authors: S. Beriwal, R. Smith, J. Vargo, R. M. Benoit
Journal: Journal of Clinical Oncology (2011)

84 Background: Cesium-131 is a relatively new radioisotope for prostate brachytherapy (PB), with limited long- term data for toxicity profiles. Here we report our 1-year follow up for severity and time to resolution of bowel toxicity using Expanded Prostatic Cancer Index Composite (EPIC) scoring. Methods: Longitudinal prospective study of 186 patients with prostate cancer treated with Cesium-131 PB at our institution were followed by EPIC recordings. The mean prostatic volume was 41.3 cm 3 and the mean prostate D90 and V100 were 105.7% and 92.4%, respectively. Patients completed surveys preoperative and at 2 weeks, 4 weeks, 3, 6, 9, and 12 months post-operatively. Outcomes were analyzed using student t-tests, with an EPIC score drop of &gt; 10 points considered clinically significant. Results: For all patients (n=186), the mean EPIC bowel summary score at baseline was 90.1 ± 11.7 compared to 72.0 ± 21.8 [mean difference 19.0 ± 1.7, p&lt;0.0001], 69.7 ± 21.4 (21.1 ± 2.0, p&lt;0.0001), 87.0 ± 13.7 (3.4 ± 1.0, p = 0.001), 90.2 ± 10.1 (0.6 ± 1.0, p = 0.508), 89.8 ± 12.8 (1.4 ± 1.1, p = .216), and 88.5 ± 13.5 (2.6 ± 1.2, p = .031) at 2 weeks, 4 weeks, 3, 6, 9, and 12 months, respectively. For patients treated with PB alone (n=128), the mean EPIC bowel summary score at baseline was 91.6 ± 10.3 compared to 70.7 ± 23.2 (20.9 ± 2.1, p&lt;0.0001), 66.1 ± 22.1 (25.3 ± 2.6, p&lt;0.0001), 86.7 ± 13.8 (4.9 ± 1.2, p&lt;0.0001), 91.4 ± 8.3 (0.8 ± 0.9, p = 0.396), 91.9 ± 10.8 (0.8 ± 1.3, p = 0.545), and 91.6 ± 10.5 (1.4 ± 1.3, p = 0.266), at 2 weeks, 4 weeks, 3, 6,9, and 12 months, respectively. For patients treated with external beam radiation therapy (EBRT) + PB (n=58), the mean EPIC bowel summary score at baseline was 89.6 ± 14.2 compared to 74.7 ± 18.6 (14.9 ± 2.6, p&lt;0.0001), 77.2 ± 17.8 (12.3 ± 2.5, p&lt;0.0001), 87.5 ± 13.7 (0.4 ± 1.8, p = 0.823), 87.9 ± 12.9 (0.3 ± 2.2, p = 0.884), 85.8 ± 15.3 (2.6 ± 2.2, p = 0.243), and 82.9 ± 16.1 (4.8 ± 2.5, p = 0.060) at 2 weeks, 4 weeks, 3, 6, 9, 12 months, respectively. Conclusions: For men undergoing PB with Cesium-131 both as monotherapy and in conjunction with EBRT, bowel symptoms returned to clinical baseline within 3 months and statistical baseline within 6 months. These results remained non-significant relative to pre-operative values up to 1-year post-PB. No significant financial relationships to disclose.
Endoscopic or percutaneous biliary drainage for Klatskin tumors? A large retrospective study.
Authors: Thomas Walter, Chia Ho, Anne M. Horgan, Andrew Warkentin, Steven Gallinger, Rob Beecroft, David W Hedley, Kongten Tan, Paul Kortan, Jennifer J. Knox
Journal: Journal of Clinical Oncology (2012)

277 Background: Controversy exists over the preferred technique of biliary drainage in patients with Klatskin tumors as few comparative studies exist. This study compared outcomes of endoscopic biliary drainage (EBD) and percutaneous transhepatic biliary drainage (PTBD). Methods: 129 patients with Klatskin tumors with an initial EBD or PTBD were identified from 01/01/1991 to 31/05/2011 and their clinical histories were retrospectively reviewed. The primary end point was the time to therapeutic success (TTS: time between the first drainage and a total bilirubin&lt;40µmol/L), estimated by Kaplan-Meier analysis. Results: The first biliary decompression procedure was EBD in 87 patients and PTBD in 42 patients. The technical (98% vs 78%, p=0.004) and therapeutic (79% vs 49%, p=0.002) successes were significantly higher in the PTBD group than EBD group, respectively; Forty four patients (51%) in the EBD group subsequently underwent a PTBD before achieving therapeutic success or starting their antitumoral treatment. The median TTS was 55 days in EBD group vs 44 days in the PTBD group (multivariate analysis: HR=0.63, 95% CI=0.41-0.99, p=0.045). In patients treated by surgery or chemotherapy +/− radiotherapy, the median time to treatment was 68 and 76 days in the PTBD group and the EBD group, respectively, p=0.76. 25% and 21% of cholangitis occurred in EBD and PTBD group, respectively (p=0.34). Conclusions: In the era where chemotherapy prolongs life even in advanced disease, shortening time to success matters. Our results suggest relying on PTB for biliary decompression would be an improved treatment strategy when treating patients with Klatskin tumor.
Interleukin-2 Enhances Angiogenesis and Preserves Cardiac Function Following Myocardial infarction
Authors: Manaf Bouchentouf, Patrick Williams, Kathy-Ann Forner, Jessica Cuerquis, Mohamed Rachid Boulassel, Pierre Paradis, Jean Pierre Routy, Ernesto Schiffrin, Jacques Galipeau
Journal: Blood (2010)
A Population (Registry) Based Analysis of the Impact of Bcr-Abl Specific Tyrosine Kinase Inhibition on Survival after Diagnosis of Philadelphia Chromosome Positive Chronic Myelogenous Leukemia..
Authors: A. Robert Turner, Joanne D Hewitt, Anmmd Kamruzzaman, Loree M. Larratt, Deborah A. Rusnak, Nanette Cox-Kennett, Andrew R. Belch
Journal: Blood (2008)
Mesenchymal Stromal Cells (MSCs) Lack Adhesion to Endothelial Cells through Selectins and b2 Integrins and Interact Dominantly Using Integrin a4b1 Activated by GTPase Rap1.
Authors: Olga Nilmaer, Melanie Giesen, Erika Deak, Victoria Lang, Johannes Leibacher, Lisa Keller, Felicia Ciuculescu, Kate Kollar, Annete Dorn, Jürgen Scheele, Tanja Nicole Hartmann, Reinhard Henschler
Journal: Blood (2010)
A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib.
Authors: Paul Richardson, David Siegel, Rachid Baz, Susan L. Kelley, Nikhil C. Munshi, Daniel Sullivan, Laura McBride, Deborah Doss, Gail Larkins, Christian Jacques, Arlene Donaldson, Kenneth C. Anderson
Journal: Blood (2009)
Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.
Authors: Saroj Vadhan-Raj, Fredrick Hagemeister, Luis E. Fayad, Xiao Zhou, Shana Sherril ORoark, Kandice Ames, Maria Alma Rodriguez, Michelle A. Fanale, Barbara Pro, Marcella M. Johnson, Peter McLaughlin, Carlos E. Bueso-Ramos, Anas Younes, Larry Kwak, Jorge Enrique Romaguera
Journal: Blood (2010)
Quantitative nuclease protection assay (qNPA) for gene expression analysis on breast cancer core biopsies.
Authors: M. C. Evangelist, J. Snider, J. Krushkal, Y. Qu, A. Kulkarni, B. Kerns, B. Seligmann, J. C. Sachdev
Journal: Journal of Clinical Oncology (2011)

49 Background: qNPA employs in situ hybridization of detection probes to cross linked mRNA, making it ideal for formalin fixed paraffin embedded (FFPE) tissue. It has been shown to measure gene expression in archived lymphoid and lung cancer tissue. We assessed the feasibility of qNPA to measure differentially expressed genes in pretreatment FFPE core breast biopsies among pathologic responders (pR) and nonresponders (pNR) to preoperative chemotherapy. Methods: We included preoperative breast cancer patients treated at our institution from 2003-09 with FFPE core biopsies. mRNA expression of 170 genes, representing oncogenic pathways or associated with anthracycline and taxane response was measured by qNPA (HTG, Tucson, AZ). Data was normalized to 3 housekeeper genes and average of 3 biologic replicates reported. Seven genes below detection in &gt; 50% samples were excluded. Expression values of 163 unique genes were analyzed for pR vs pNR with dChip software. Empirical FDR was estimated using 1,000 permutations of sample labels. Results: Treatment and response: Sample failure: 6/57 (10%). pR vs pNR did not separate on hierarchical clustering. FLJ12650 and IGFBP2 showed lower expression in pR vs pNR with fold changes of 4.09 and 2.40, respectively (p &lt; 0.01; median FDR: 1/163). FLJ12650 was significant (p &lt; 0.01, median FDR: 0/163) when patients receiving anthracycline ± taxane were analyzed (groups 1-3) and showed a trend (p &lt; 0.05) in group 1 alone. Conclusions: qNPA for limited available FFPE tissue from core biopsies is feasible with acceptable sample failure rates. Small sample size and number of analyzed genes limited definitive conclusion about informative genes in our study. Our FLJ12650 results, a gene coding for membrane Na+/K+ ATPase interacting protein, are consistent with previous findings of overexpression in pNR to anthracyclines + taxanes (Hess et al, JCO 2006, Vol 24; 4236) using fresh tissue. Future qNPA validation of predictive markers, identified by whole transcriptome analysis in a homogenous cohort may provide more definitive results. [Table: see text]
In Vivo Platelet Activation and Its In Vitro Inhibition by Prasugrel's Active Metabolite In Adolescents with Sickle Cell Disease
Authors: Andrew L. Frelinger, Joseph A. Jakubowski, Julie K. Brooks, Anu Nigam, Michelle A. Berny-Lang, Marc R. Barnard, Matthew M. Heeney, Alan D. Michelson
Journal: Blood (2011)
Phase III, randomized, open-label study of triweekly docetaxel versus biweekly docetaxel as treatments for advanced hormone-refractory prostate cancer: Findings from an interim safety analysis of the Finnish Uro-oncological Group Study 1-2003.
Authors: P. Hervonen, H. Joensuu, T. K. Joensuu, P. Nyandoto, M. Luukkaa, S. Nilsson, A. E. Hemminki, R. Asola, T. Luukkaala, P. Kellokumpu-Lehtinen
Journal: Journal of Clinical Oncology (2011)

129 Background: Docetaxel (T) administered at every three weeks is standard treatment for advanced HRPC. We compared 2-weekly to 3-weekly T as first- or second-line chemotherapy of advanced HRPC in this prospective randomized multicenter trial. Methods: 360 pts were randomly allocated to receive T 75 mg/m 2 i.v. d1 q3 wks (tT) or 50 mg/m 2 i.v. d1 and d 14, q4 wks (bT) from March 2004 to May 2009. Prednisolon 10 mg/day was administered in both groups. The groups were well balanced according to the WHO performance status, mean age (70 vs. 68, range 45–87), and the median serum PSA level at study entry (109 vs. 98 μ g/L, range 11–1,490). The primary endpoint was TTF. Study identifier: NCT00255606 . Results: 158 pts (tT, 79; bT, 79) were included in this preplanned interim safety analysis. 567 and 487 cycles were administered in the tT and bT groups, respectively. The most common grade 3–4 adverse events (expressed as %/cycles) in tT /bT were neutropenia 20%/14%, infection with/without neutropenia 8%/3%, fatigue 3%/ 3%, febrile neutropenia 2%/1%, and bone pain 2%/1%. Serious adverse events occurred more frequently in tT (n=60, 10.6% of cycles) than in bT (n=29, 6.0%, p=0.012). One pt. died from coronary infarction and one was diagnosed with ALL (both in bT group). 30 pts (38%) in bT group and 22 pts (28%) in tT group were receiving treatment at 6 months. (p=0.176). Conclusions: Biweekly T has been better tolerated than the conventional triweekly T with fewer serious adverse events and may be associated with similar efficacy. [Table: see text]
Validation of the Use of Apixaban As an Alternate Anticoagulant for the Management of Patients with Heparin-Induced Thrombocytopenia.
Authors: Jeanine M. Walenga, Margaret Prechel, Debra Hoppensteadt, Vicki Escalante, Talhah Chaudhry, Walter Jeske, Mamdouh Bakhos
Journal: Blood (2012)
Patterns of Prior Treatment and Bleeds Among Patients with Severe Hemophilia a: Impact on Frequency of Dosing with Bay 81-8973 in the Leopold I Trial
Authors: Nikki Church, Rajeev Ayyagari, Jennifer Pocoski, Gautam Sajeev, Sneha S Kelkar, Ella X Du, Monika Mass-Enriquez, Jipan Xie
Journal: Blood (2015)
Safety of Multiple Doses of CAR T Cells
Authors: Rayne H. Rouce, Kristen Fousek, Nabil Ahmed, Stephen Gottschalk, Barbara Savoldo, Gianpietro Dotti, Carlos A. Ramos, Chrystal Louis, Cliona M. Rooney, Malcolm K. Brenner, Helen E. Heslop
Journal: Blood (2015)